Arvinas, Inc. (ARVN) shares soared 8.8% in the last trading session to close at $9.03. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Shares of Arvinas ARVN plummeted 52.7% on Tuesday after the company and partner, Pfizer PFE, announced mixed results from a late-stage breast cancer study of its lead candidate, vepdegestrant.

Arvinas, Inc. (ARVN) closed the last trading session at $17.70, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target of $57.00. The company’s shares closed yesterday ...